Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996190 | 0.84 | BRD4 (0.40) | PIK3C3PIK3CAPTGS1TRPV1KDM4E | |
| SCHEMBL17946826 | 0.82 | PIK3CA (0.57) | PIK3C3PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17946250 | 0.80 | PIK3CD (0.50) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL24609150 | 0.80 | SLC22A12 (0.41) | PIK3CAPIK3CDPIK3CBPIK3CGTRPV1 | |
| SCHEMBL18595671 | 0.79 | CYP17A1 (0.41) | PIK3C3PIK3CAKDM4EALDH1A1LMNA | |
| SCHEMBL24576532 | 0.79 | PIK3C3 (0.48) | PIK3C3PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17946279 | 0.76 | PIK3CD (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGTRPV1 | |
| SCHEMBL23362710 | 0.76 | PIK3C3 (0.46) | PIK3C3PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL855688 | 0.76 | PIK3C3 (0.46) | PIK3C3PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL116876 | 0.76 | PIK3CA (0.48) | PIK3C3PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | PIK3C3 32/4885PIK3CA 8/4885PIK3CD 22/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | PIK3C3 32/4885PIK3CA 8/4885PIK3CD 22/4885 |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | PIK3C3 32/4885PIK3CA 8/4885PIK3CD 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.